Clinical Trial

Electrochemotherapy for Recurrent Vulvar Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase I/II interventional study evaluates the effectiveness and safety of electrochemotherapy (ECT) as neoadjuvant treatment for local recurrence of vulvar cancer. Electrochemotherapy combines intravenous administration of bleomycin with delivery of electric pulses to the tumor area, increasing drug uptake into cancer cells. The main goal is to assess tumor response and reduce the need for mutilating surgical procedures, thereby improving quality of life in women with recurrent vulvar cancer. Participants will be followed prospectively and treatment outcomes will be evaluated using RECIST criteria and adverse events using CTCAE v5.0.
Trial Details
NCT Number NCT07443475
Lead Sponsor Institute of Oncology Ljubljana
Conditions Vulvar Cancer, Recurrent Vulvar Cancer
Enrollment 13 participants
Start Date 2021-09-01
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-02